168 related articles for article (PubMed ID: 37542632)
1. Clinical characteristics and prognosis of postpartum breast cancer.
Paik PS; Choi JE; Lee SW; Lee YJ; Kang YJ; Lee HJ; Bae SY;
Breast Cancer Res Treat; 2023 Nov; 202(2):275-286. PubMed ID: 37542632
[TBL] [Abstract][Full Text] [Related]
2. Association Between Postpartum Breast Cancer Diagnosis and Metastasis and the Clinical Features Underlying Risk.
Goddard ET; Bassale S; Schedin T; Jindal S; Johnston J; Cabral E; Latour E; Lyons TR; Mori M; Schedin PJ; Borges VF
JAMA Netw Open; 2019 Jan; 2(1):e186997. PubMed ID: 30646210
[TBL] [Abstract][Full Text] [Related]
3. Young-Onset Breast Cancer Outcomes by Time Since Recent Childbirth in Utah.
Zhang Z; Bassale S; Jindal S; Fraser A; Guinto E; Anderson W; Mori M; Smith KR; Schedin P
JAMA Netw Open; 2022 Oct; 5(10):e2236763. PubMed ID: 36239933
[TBL] [Abstract][Full Text] [Related]
4. Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes.
Jindal S; Pennock ND; Sun D; Horton W; Ozaki MK; Narasimhan J; Bartlett AQ; Weinmann S; Goss PE; Borges VF; Xia Z; Schedin P
Nat Commun; 2021 Nov; 12(1):6341. PubMed ID: 34732713
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
6. Overall survival is the lowest among young women with postpartum breast cancer.
Shagisultanova E; Gao D; Callihan E; Parris HJ; Risendal B; Hines LM; Slattery ML; Baumgartner K; Schedin P; John EM; Borges VF
Eur J Cancer; 2022 Jun; 168():119-127. PubMed ID: 35525161
[TBL] [Abstract][Full Text] [Related]
7. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
[TBL] [Abstract][Full Text] [Related]
8. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
11. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
13. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
14. HR+/Her2- breast cancer in pre-menopausal women: The impact of younger age on clinical characteristics at diagnosis, disease management and survival.
De Camargo Cancela M; Comber H; Sharp L
Cancer Epidemiol; 2016 Dec; 45():162-168. PubMed ID: 27846443
[TBL] [Abstract][Full Text] [Related]
15. Negative estrogen receptors and positive progesterone receptors breast cancers.
Delvallée J; Etienne C; Arbion F; Vildé A; Body G; Ouldamer L
J Gynecol Obstet Hum Reprod; 2021 Feb; 50(2):101928. PubMed ID: 33022450
[TBL] [Abstract][Full Text] [Related]
16. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
17. A long-term retrospective comparative study of the oncological outcomes of 598 very young (≤35 years) and young (36-45 years) breast cancer patients.
Szollár A; Újhelyi M; Polgár C; Oláh E; Pukancsik D; Rubovszky G; Udvarhelyi N; Kovács T; Sávolt Á; Kenessey I; Mátrai Z
Eur J Surg Oncol; 2019 Nov; 45(11):2009-2015. PubMed ID: 31189512
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
[TBL] [Abstract][Full Text] [Related]
19. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
